Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Should You Sell?

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped down before the market opened on Friday . The stock had previously closed at $10.94, but opened at $10.62. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $10.62, with a volume of 1,963 shares traded.

Analyst Ratings Changes

Separately, The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR has an average rating of “Hold”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 3.1%

The firm has a market cap of $18.03 billion, a P/E ratio of 13.95, a P/E/G ratio of 0.87 and a beta of 0.19. The business’s 50-day moving average is $11.05 and its two-hundred day moving average is $9.52. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Friday, January 30th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.09. The business had revenue of $966.53 million during the quarter, compared to the consensus estimate of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.82% and a return on equity of 13.70%. As a group, analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.